Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010

Thorax

Volumn 65, Issue SUPPL. 2, 2010, Pages

  Davies, Helen E ^a,b   Davies, Robert J O ^a   Davies, Christopher W H ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIOLOGY; BACTERIUM CULTURE; BRITISH THORACIC SOCIETY PLEURAL DISEASE GUIDELINE 2010; BRONCHOSCOPY; HOSPITAL INFECTION; HUMAN; LUNG INFECTION; LYMPHOMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NUTRITION; PATHOPHYSIOLOGY; PEER REVIEW; PLEURA EMPYEMA; PLEURA FLUID; PLEURAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; THORAX DRAINAGE; THROMBOSIS PREVENTION; ADULT; ALGORITHM; BACTERIAL INFECTION; CHRONIC DISEASE; DISEASE TRANSMISSION; EVIDENCE BASED MEDICINE; METHODOLOGY; MICROBIOLOGY; PLEURA DISEASE; PLEURA EFFUSION; PROGNOSIS; REVIEW; TUBE; WOUND DRAINAGE;

ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHOSCOPY; CHEST TUBES; CHRONIC DISEASE; DRAINAGE; EVIDENCE-BASED MEDICINE; HUMANS; PLEURAL DISEASES; PLEURAL EFFUSION; PROGNOSIS;

EID: 77956054328     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.137000     Document Type: Article

References (212)

1. Ferguson AD, Prescott RJ, Selkon JB, et al. The clinical course and management of thoracic empyema. Q J Med 1996;89:285-9. (3).
2. Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006;174:817-23. (1++).
3. Finley C, Clifton J, Fitzgerald JM, et al. Empyema: an increasing concern in Canada. Can Respir J 2008;15:85-9. (2+).
4. Meyer JA. Gotthard Bulau and closed water-seal drainage for empyema, 1875-1891. Ann Thorac Surg 1989;48:597-9. (4).
5. Peters RM. Empyema thoracis: historical perspective. Ann Thorac Surg 1989;48:306-8. (4).
6. Heffner JE. Diagnosis and management of thoracic empyemas. Curr Opin Pulm Med 1996;2:198-205. (4).
7. Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993;16(Suppl 4):S248-55. (4).
8. Stiles QR, Lindesmith GG, Tucker BL, et al. Pleural empyema in children. Ann Thorac Surg 1970;10:37-44. (3).
9. Alfageme I, Munoz F, Pena N, et al. Empyema of the thorax in adults. Etiology, microbiologic findings, and management. Chest 1993;103:839-43. (3).
10. Wallenhaupt SL. Surgical management of thoracic empyema. J Thorac Imaging 1991;6:80-8. (3).
11. Tilllett WS, Sherry S. The effect in patients of streptococcal fibrinolysin and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest 1949;28:173-90. (3).
12. Wait MA, Sharma S, Hohn J, et al. A randomized trial of empyema therapy. Chest 1997;111:1548-51. (1-).
13. Farjah F, Symons RG, Krishnadasan B, et al. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg 2007;133:346-51. (2+).
14. Wang NS. Anatomy of the pleura. Clin Chest Med 1998;19:229-40. (4).
15. Agostoni E, Zocchi L. Mechanical coupling and liquid exchanges in the pleural space. Clin Chest Med 1998;19:241-60. (4).
16. Trotter CL, Stuart JM, George R, et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008;14:727-33. (3).
17. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med 1980;69:507-12. (2+).
18. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest 1978;74:170-3. (3).
19. American Thoracic Society. Management of nontuberculous empyema: a statement of the subcommittee on surgery. Am Rev Respir Dis 1962;935-6. (4).
20. Aleman C, Alegre J, Monasterio J, et al. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond) 2003;105:601-7. (3).
21. Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997;10:2411-18. (4).
22. Good JT Jr, Taryle DA, Maulitz RM, et al. The diagnostic value of pleural fluid pH. Chest 1980;78:55-9. (3).
23. Light RW, MacGregor MI, Ball WC Jr, et al. Diagnostic significance of pleural fluid pH and PCO2. Chest 1973;64:591-6. (2+).
24. Potts DE, Levin DC, Sahn SA. Pleural fluid pH in parapneumonic effusions. Chest 1976;70:328-31. (2+).
25. Potts DE, Taryle DA, Sahn SA. The glucose-pH relationship in parapneumonic effusions. Arch Intern Med 1978;138:1378-80. (2+).
26. Sasse SA, Causing LA, Mulligan ME, et al. Serial pleural fluid analysis in a new experimental model of empyema. Chest 1996;109:1043-8. (2+).
27. Idell S, Girard W, Koenig KB, et al. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991;144:187-94. (2+).
28. Sahn SA, Reller LB, Taryle DA, et al. The contribution of leukocytes and bacteria to the low pH of empyema fluid. Am Rev Respir Dis 1983;128:811-15. (2+).
29. Ali I, Unruh H. Management of empyema thoracis. Ann Thorac Surg 1990;50:355-9. (3).
30. Ashbaugh DG. Empyema thoracis. Factors influencing morbidity and mortality. Chest 1991;99:1162-5. (3).
31. Bartlett JG, Gorbach SL, Thadepalli H, et al. Bacteriology of empyema. Lancet 1974;1:338-40. (3).
32. Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. Chest 1993;103:1502-7. (3).
33. Galea JL, De Souza A, Beggs D, et al. The surgical management of empyema thoracis. J R Coll Surg Edinb 1997;42:15-18. (3).
34. Hughes CE, Van Scoy RE. Antibiotic therapy of pleural empyema. Semin Respir Infect 1991;6:94-102. (4).
35. Landreneau RJ, Keenan RJ, Hazelrigg SR, et al. Thoracoscopy for empyema and hemothorax. Chest 1996;109:18-24. (3).
36. LeMense GP, Strange C, Sahn SA. Empyema thoracis. Therapeutic management and outcome. Chest 1995;107:1532-7. (3).
37. Lemmer JH, Botham MJ, Orringer MB. Modern management of adult thoracic empyema. J Thorac Cardiovasc Surg 1985;90:849-55. (3).
38. Mandal AK, Thadepalli H. Treatment of spontaneous bacterial empyema thoracis. J Thorac Cardiovasc Surg 1987;94:414-18. (3).
39. Mavroudis C, Symmonds JB, Minagi H, et al. Improved survival in management of empyema thoracis. J Thorac Cardiovasc Surg 1981;82:49-57. (3).
40. Sherman MM, Subramanian V, Berger RL. Managment of thoracic empyema. Am J Surg 1977;133:474-9. (3).
41. Smith JA, Mullerworth MH, Westlake GW, et al. Empyema thoracis: 14-year experience in a teaching center. Ann Thorac Surg 1991;51:39-42. (3).
42. Storm HK, Krasnik M, Bang K, et al. Treatment of pleural empyema secondary to pneumonia: thoracocentesis regimen versus tube drainage. Thorax 1992;47:821-4. (3).
43. Van WC III, Narrod J, Hopeman A. The role of early limited thoracotomy in the treatment of empyema. J Thorac Cardiovasc Surg 1988;96:436-9. (3).
44. Varkey B, Rose HD, Kutty CP, et al. Empyema thoracis during a ten-year period. Analysis of 72 cases and comparison to a previous study (1952 to 1967) Arch Intern Med 1981;141:1771-6. (3).
45. Chen KY, Hsueh PR, Liaw YS, et al. A 10-year experience with bacteriology of acute thoracic empyema: emphasis on Klebsiella pneumoniae in patients with diabetes mellitus. Chest 2000;117:1685-9. (3).
46. Civen R, Jousimies-Somer H, Marina M, et al. A retrospective review of cases of anaerobic empyema and update of bacteriology. Clin Infect Dis 1995;20(Suppl 2):S224-9. (3).
47. Lin YC, Chen HJ, Liu YH, et al. A 30-month experience of thoracic empyema in a tertiary hospital: emphasis on differing bacteriology and outcome between the medical intensive care unit (MICU) and medical ward. South Med J 2008;101:484-9. (3).
48. Tu CY, Hsu WH, Hsia TC, et al. The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit. Intensive Care Med 2006;32:570-6. (3).
49. Mandal AK, Thadepalli H, Mandal AK, et al. Outcome of primary empyema thoracis: therapeutic and microbiologic aspects. Ann Thorac Surg 1998;66:1782-6. (3).
50. Rahman NM, Chapman SJ, Davies RJ. The approach to the patient with a parapneumonic effusion. Clin Chest Med 2006;27:253-66. (4).
51. Ko SC, Chen KY, Hsueh PR, et al. Fungal empyema thoracis: an emerging clinical entity. Chest 2000;117:1672-8. (3).
52. Dhiensiri T, Puapairoj S, Susaengrat W. Pulmonary melioidosis: clinical-radiologic correlation in 183 cases in northeastern Thailand. Radiology 1988;166:711-15. (3).
53. Lyche KD, Jensen WA. Pleuropulmonary amebiasis. Semin Respir Infect 1997;12:106-12. (4).
54. Prasad R, Verma SK. A study of anaerobic infection in patients with empyema thoracis. J Int Med India 2005;8:75-9. (3).
55. Saglani S, Harris KA, Wallis C, et al. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. Arch Dis Child 2005;90:70-3. (2+).
56. Cham CW, Haq SM, Rahamim J. Empyema thoracis: a problem with late referral? Thorax 1993;48:925-7. (3).
57. Davies CW, Kearney SE, Gleeson FV, et al. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999;160:1682-7. (3).
58. Heffner JE, McDonald J, Barbieri C, et al. Management of parapneumonic effusions. An analysis of physician practice patterns. Arch Surg 1995;130:433-8. (3).
59. Sasse S, Nguyen TK, Mulligan M, et al. The effects of early chest tube placement on empyema resolution. Chest 1997;111:1679-83. (1+).
60. Blosser SA, Zimmerman HE, Stauffer JL. Do autopsies of critically ill patients reveal important findings that were clinically undetected? Crit Care Med 1998;26:1332-6. (3).
61. Davidson BL. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients. Haemostasis 2000;30(Suppl 2):77-81. (4).
62. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278-88. (1+).
63. Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest 2003;124:357S-63. (1+).
64. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338-400S. (1-).
65. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9. (1++).
66. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3): iii1-55. (1++).
67. Hansson LO, Hedlund JU, Ortqvist AB. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest 1997;57:111-18. (3).
68. Ortqvist A, Hedlund J, Wretlind B, et al. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995;27:457-62. (3).
69. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-25. (2+).
70. Chalmers JD, Singanayagam A, Murray MP, et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with communityacquired pneumonia. Thorax 2009;64:556-8. (3).
71. Stavas J, vanSonnenberg E, Casola G, et al. Percutaneous drainage of infected and noninfected thoracic fluid collections. J Thorac Imaging 1987;2:80-7. (4).
72. Eibenberger KL, Dock WI, Ammann ME, et al. Quantification of pleural effusions: sonography versus radiography. Radiology 1994;191:681-4. (2+).
73. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988;138:184-234. (4).
74. Strange C. Effusions caused by gastrointestinal disease. In: Light RW, Lee YCG, eds. Textbook of pleural diseases. London: Hodder Arnold, 2008:465-70. (4).
75. Yang PC, Luh KT, Chang DB, et al. Value of sonography in determining the nature of pleural effusion: analysis of 320 cases. AJR Am J Roentgenol 1992;159:29-33. (3).
76. Chen KY, Liaw YS, Wang HC, et al. Sonographic septation: a useful prognostic indicator of acute thoracic empyema. J Ultrasound Med 2000;19:837-43. (2+).
77. Himelman RB, Callen PW. The prognostic value of loculations in parapneumonic pleural effusions. Chest 1986;90:852-6. (3).
78. Muller NL. Imaging of the pleura. Radiology 1993;186:297-309. (4).
79. Stark DD, Federle MP, Goodman PC, et al. Differentiating lung abscess and empyema: radiography and computed tomography. AJR Am J Roentgenol 1983;141:163-7. (3).
80. Aquino SL, Webb WR, Gushiken BJ. Pleural exudates and transudates: diagnosis with contrast-enhanced CT. Radiology 1994;192:803-8. (3).
81. Takasugi JE, Godwin JD, Teefey SA. The extrapleural fat in empyema: CT appearance. Br J Radiol 1991;64:580-3. (3).
82. Waite RJ, Carbonneau RJ, Balikian JP, et al. Parietal pleural changes in empyema: appearances at CT. Radiology 1990;175:145-50. (3).
83. Kearney SE, Davies CW, Davies RJ, et al. Computed tomography and ultrasound in parapneumonic effusions and empyema. Clin Radiol 2000;55:542-7. (3).
84. Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74. (1++).
85. Heffner JE, Brown LK, Barbieri C, et al. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995;151:1700-8. (1+).
86. Light RW. A new classification of parapneumonic effusions and empyema. Chest 1995;108:299-301. (4).
87. Poe RH, Marin MG, Israel RH, et al. Utility of pleural fluid analysis in predicting tube thoracostomy/decortication in parapneumonic effusions. Chest 1991;100:963-7. (3).
88. National Patient Safety Agency (NPSA). Rapid Response Report: Risks of chest drain insertion (Reference NPSA/2008/RRR03). 2008:1-10. (4).
89. Diacon AH, Brutsche MH, Soler M. Accuracy of pleural puncture sites: a prospective comparison of clinical examination with ultrasound. Chest 2003;123:436-41. (2+).
90. Jones PW, Moyers JP, Rogers JT, et al. Ultrasound-guided thoracentesis: is it a safer method? Chest 2003;123:418-23. (2+).
91. Mattison LE, Coppage L, Alderman DF, et al. Pleural effusions in the medical ICU: prevalence, causes, and clinical implications. Chest 1997;111:1018-23. (3).
92. Rahman NM, Mishra EK, Davies HE, et al. Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose. Am J Respir Crit Care Med 2008;178:483-90. (2+).
93. Jimenez CD, Diaz G, Perez-Rodriguez E, et al. Modification of pleural fluid pH by local anesthesia. Chest 1999;116:399-402. (2+).
94. Cheng DS, Rodriguez RM, Rogers J, et al. Comparison of pleural fluid pH values obtained using blood gas machine, pH meter, and pH indicator strip. Chest 1998;114:1368-72. (2+).
95. Lesho EP, Roth BJ. Is pH paper an acceptable, low-cost alternative to the blood gas analyzer for determining pleural fluid pH? Chest 1997;112:1291-2. (2+).
96. Pine JR, Hollman JL. Elevated pleural fluid pH in Proteus mirabilis empyema. Chest 1983;84:109-11. (3).
97. Maskell NA, Gleeson FV, Darby M, et al. Diagnostically significant variations in pleural fluid pH in loculated parapneumonic effusions. Chest 2004;126:2022-4. (3).
98. Akarsu S, Kurt AN, Dogan Y, et al. The differential diagnostic values of cytokine levels in pleural effusions. Mediat Inflamm 2005;2005:2-8. (3).
99. Chen SC, Chen W, Hsu WH, et al. Role of pleural fluid C-reactive protein concentration in discriminating uncomplicated parapneumonic pleural effusions from complicated parapneumonic effusion and empyema. Lung 2006;184:141-5. (2+).
100. Porcel JM, Vives M, Esquerda A. Tumor necrosis factor-alpha in pleural fluid: a marker of complicated parapneumonic effusions. Chest 2004;125:160-4. (2+).
101. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707-10. (2+).
102. Huang HC, Chang HY, Chen CW, et al. Predicting factors for outcome of tube thoracostomy in complicated parapneumonic effusion for empyema. Chest 1999;115:751-6. (3).
103. British Thoracic Society. Guidance for the local implementation of local trust policies for the safe insertion of chest drains for pleural effusions in adults, following the NPSA Rapid Response Report. http://www.brit-thoracic.org. uk/Portals/0/Clinical%20Information/Pleural%20Disease/chestdrain-adults.pdf (accessed 2009). (4).
104. Merriam MA, Cronan JJ, Dorfman GS, et al. Radiographically guided percutaneous catheter drainage of pleural fluid collections. AJR Am J Roentgenol 1988;151:1113-16. (3).
105. Silverman SG, Mueller PR, Saini S, et al. Thoracic empyema: management with image-guided catheter drainage. Radiology 1988;169:5-9. (3).
106. Stavas J, vanSonnenberg E, Casola G, et al. Percutaneous drainage of infected and noninfected thoracic fluid collections. J Thorac Imaging 1987;2:80-7. (3).
107. Ulmer JL, Choplin RH, Reed JC. Image-guided catheter drainage of the infected pleural space. J Thorac Imaging 1991;6:65-73. (4).
108. Westcott JL. Percutaneous catheter drainage of pleural effusion and empyema. AJR Am J Roentgenol 1985;144:1189-93. (3).
109. Crouch JD, Keagy BA, Delany DJ. "Pigtail" catheter drainage in thoracic surgery. Am Rev Respir Dis 1987;136:174-5. (3).
110. Hunnam GR, Flower CD. Radiologically-guided percutaneous catheter drainage of empyemas. Clin Radiol 1988;39:121-6. (3).
111. vanSonnenberg E, Nakamoto SK, Mueller PR, et al. CT-and ultrasound-guided catheter drainage of empyemas after chest-tube failure. Radiology 1984;151:349-53. (3).
112. Klein JS, Schultz S, Heffner JE. Interventional radiology of the chest: image-guided percutaneous drainage of pleural effusions, lung abscess, and pneumothorax. AJR Am J Roentgenol 1995;164:581-8. (4).
113. Lee KS, Im JG, Kim YH, et al. Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study. Radiology 1991;179:771-5. (3).
114. Miller KS, Sahn SA. Chest tubes. Indications, technique, management and complications. Chest 1987;91:258-64. (4).
115. Munnell ER. Thoracic drainage. Ann Thorac Surg 1997;63:1497-502. (4).
116. Bartlett JG. Antibiotics in lung abscess. Semin Respir Infect 1991;6:103-11. (4).
117. Neild JE, Eykyn SJ, Phillips I. Lung abscess and empyema. Q J Med 1985;57:875-82. (3).
118. Minton EJ, Macfarlane JT. Antibiotic resistant Streptococcus pneumoniae. Thorax 1996;51(Suppl 2):S45eS50. (4).
119. Jerng JS, Hsueh PR, Teng LJ, et al. Empyema thoracis and lung abscess caused by viridans streptococci. Am J Respir Crit Care Med 1997;156:1508-14. (3).
120. Wong CA, Donald F, Macfarlane JT. Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients. Thorax 1995;50:1093-6. (3).
121. Nathwani D, Wood MJ. Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs 1993;45:866-94. (4).
122. Scaglione F, Raichi M, Fraschini F. Serum protein binding and extravascular diffusion of methoxyimino cephalosporins. Time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate. J Antimicrob Chemother 1990;26(Suppl A):1-10. (2+).
123. Taryle DA, Good JT Jr, Morgan EJ III, et al. Antibiotic concentrations in human parapneumonic effusions. J Antimicrob Chemother 1981;7:171-7. (2+).
124. Teixeira LR, Villarino MA. Antibiotic treatment of patients with pneumonia and pleural effusion. Curr Opin Pulm Med 1998;4:230-4. (4).
125. Shohet I, Yellin A, Meyerovitch J, et al. Pharmacokinetics and therapeutic efficacy of gentamicin in an experimental pleural empyema rabbit model. Antimicrob Agents Chemother 1987;31:982-5. (2+).
126. Teixeira LR, Sasse SA, Villarino MA, et al. Antibiotic levels in empyemic pleural fluid. Chest 2000;117:1734-9. (4).
127. Thys JP, Serruys-Schoutens E, Rocmans P, et al. Amikacin concentrations in uninfected postthoracotomy pleural fluid and in serum after intravenous and intrapleural injection. Chest 1984;85:502-5. (3).
128. Thys JP, Vanderhoeft P, Herchuelz A, et al. Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas. Chest 1988;93:530-2. (3).
129. Huchon G, Woodhead M. Guidelines for management of adult community-acquired lower respiratory tract infections. European Study on Community Acquired Pneumonia (ESOCAP) Committee. Eur Respir J 1998;11:986-91. (4).
130. Hammond JM, Potgieter PD, Hanslo D, et al. The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. Chest 1995;108:937-41. (3).
131. Shinzato T, Saito A. A mechanism of pathogenicity of "Streptococcus milleri group" in pulmonary infection: synergy with an anaerobe. J Med Microbiol 1994;40:118-23. (2+).
132. Shinzato T, Saito A. The Streptococcus milleri group as a cause of pulmonary infections. Clin Infect Dis 1995;21(Suppl 3):S238-43. (3).
133. Liapakis IE, Kottakis I, Tzatzarakis MN, et al. Penetration of newer quinolones in the empyema fluid. Eur Respir J 2004;24:466-70. (2+).
134. Liapakis IE, Light RW, Pitiakoudis MS, et al. Penetration of clarithromycin in experimental pleural empyema model fluid. Respiration 2005;72:296-300. (2+).
135. Sahn SA. Management of complicated parapneumonic effusions. Am Rev Respir Dis 1993;148:813-17. (4).
136. Finegold SM, Wexler HM. Present studies of therapy for anaerobic infections. Clin Infect Dis 1996;23(Suppl 1):S9-14. (4).
137. Kroboth FJ, Yu VL, Reddy SC, et al. Clinicoradiographic correlation with the extent of Legionnaire disease. AJR Am J Roentgenol 1983;141:263-8. (2+).
138. Randolph KA, Beekman JF. Legionnaires' disease presenting with empyema. Chest 1979;75:404-6. (3).
139. Fine NL, Smith LR, Sheedy PF. Frequency of pleural effusions in mycoplasma and viral pneumonias. N Engl J Med 1970;283:790-3. (3).
140. Mansel JK, Rosenow EC III, Smith TF, et al. Mycoplasma pneumoniae pneumonia. Chest 1989;95:639-46. (3).
141. Department of Health. Screening for meticillin-resistant Staphylococcus aureus (MRSA) colonisation. A strategy for NHS Trusts: a summary of best practice. http://www.dh.gov.uk/reducingmrsa (accessed 2006). (4).
142. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-careassociated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-62. (2+).
143. Maclayton DO, Hall RG. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007;41:235-44. (2++).
144. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84. (2+).
145. Aye RW, Froese DP, Hill LD. Use of purified streptokinase in empyema and hemothorax. Am J Surg 1991;161:560-2. (3).
146. Bergh NP, Ekroth R, Larsson S, et al. Intrapleural streptokinase in the treatment of haemothorax and empyema. Scand J Thorac Cardiovasc Surg 1977;11:265-8. (3).
147. Berglin E, Ekroth R, Teger-Nilsson AC, et al. Intrapleural instillation of streptokinase. Effects on systemic fibrinolysis. Thorac Cardiovasc Surg 1981;29:124-6. (3).
148. Bouros D, Schiza S, Panagou P, et al. Role of streptokinase in the treatment of acute loculated parapneumonic pleural effusions and empyema. Thorax 1994;49:852-5. (3).
149. Chin NK, Lim TK. Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions. Chest 1997;111:275-9. (2-).
150. Cohen ML, Finch IJ. Transcatheter intrapleural urokinase for loculated pleural effusion. Chest 1994;105:1874-6. (3).
151. Davies CW, Lok S, Davies RJ. The systemic fibrinolytic activity of intrapleural streptokinase. Am J Respir Crit Care Med 1998;157:328-30. (2+).
152. Fraedrich G, Hofmann D, Effenhauser P, et al. Instillation of fibrinolytic enzymes in the treatment of pleural empyema. Thorac Cardiovasc Surg 1982;30:36-8. (3).
153. Godley PJ, Bell RC. Major hemorrhage following administration of intrapleural streptokinase. Chest 1984;86:486-7. (3).
154. Henke CA, Leatherman JW. Intrapleurally administered streptokinase in the treatment of acute loculated nonpurulent parapneumonic effusions. Am Rev Respir Dis 1992;145:680-4. (3).
155. Jerjes-Sanchez C, Ramirez-Rivera A, Elizalde JJ, et al. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest 1996;109:1514-19. (3).
156. Laisaar T, Puttsepp E, Laisaar V. Early administration of intrapleural streptokinase in the treatment of multiloculated pleural effusions and pleural empyemas. Thorac Cardiovasc Surg 1996;44:252-6. (3).
157. Mitchell ME, Alberts WM, Chandler KW, et al. Intrapleural streptokinase in management of parapneumonic effusions. Report of series and review of literature. J Fla Med Assoc 1989;76:1019-22. (3).
158. Moulton JS, Moore PT, Mencini RA. Treatment of loculated pleural effusions with transcatheter intracavitary urokinase. AJR Am J Roentgenol 1989;153:941-5. (3).
159. Moulton JS, Benkert RE, Weisiger KH, et al. Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase. Chest 1995;108:1252-9. (3).
160. Ogirala RG, Williams MH Jr. Streptokinase in a loculated pleural effusion. Effectiveness determined by site of instillation. Chest 1988;94:884-6. (3).
161. Park CS, Chung WM, Lim MK, et al. Transcatheter instillation of urokinase into loculated pleural effusion: analysis of treatment effect. AJR Am J Roentgenol 1996;167:649-52. (3).
162. Pollak JS, Passik CS. Intrapleural urokinase in the treatment of loculated pleural effusions. Chest 1994;105:868-73. (3).
163. Porter J, Banning AP. Intrapleural streptokinase. Thorax 1998;53:720. (3).
164. Robinson LA, Moulton AL, Fleming WH, et al. Intrapleural fibrinolytic treatment of multiloculated thoracic empyemas. Ann Thorac Surg 1994;57:803-13. (3).
165. Roupie E, Bouabdallah K, Delclaux C, et al. Intrapleural administration of streptokinase in complicated purulent pleural effusion: a CT-guided strategy. Intensive Care Med 1996;22:1351-3. (3).
166. Ryan JM, Boland GW, Lee MJ, et al. Intracavitary urokinase therapy as an adjunct to percutaneous drainage in a patient with a multiloculated empyema. AJR Am J Roentgenol 1996;167:643-7. (3).
167. Taylor RF, Rubens MB, Pearson MC, et al. Intrapleural streptokinase in the management of empyema. Thorax 1994;49:856-9. (3).
168. Temes RT, Follis F, Kessler RM, et al. Intrapleural fibrinolytics in management of empyema thoracis. Chest 1996;110:102-6. (3).
169. Willsie-Ediger SK, Salzman G, Reisz G, et al. Use of intrapleural streptokinase in the treatment of thoracic empyema. Am J Med Sci 1990;300:296-300. (3).
170. Bouros D, Schiza S, Patsourakis G, et al. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med 1997;155:291-5. (1+).
171. Bouros D, Schiza S, Tzanakis N, et al. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med 1999;159:37-42. (1+).
172. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of parapneumonic effusions and empyema. Cochrane Database Syst Rev 2004:CD002312. (1++).
173. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997;52:416-21. (1+).
174. Diacon AH, Theron J, Schuurmans MM, et al. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004;170:49-53. (1++).
175. Misthos P, Sepsas E, Konstantinou M, et al. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. Eur J Cardiothorac Surg 2005;28:599-603. (1-)
176. Talib SH, Verma GR, Arshad M, et al. Utility of intrapleural streptokinase in management of chronic empyemas. J Assoc Physicians India 2003;51:464-8. (1+).
177. Thomson AH, Hull J, Kumar MR, et al. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002;57:343-7. (1+).
178. Tuncozgur B, Ustunsoy H, Sivrikoz MC, et al. Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. Int J Clin Pract 2001;55:658-60. (1+).
179. Bilaceroglu S, Cagerici U, Cakan A. Management of complicated parapneumonic effusions with image-guided drainage and intrapleural urokinase or streptokinase: a controlled randomized trial. Eur Respir J 1997;10:325S. (1-).
180. Strange C, Allen ML, Harley R, et al. Intrapleural streptokinase in experimental empyema. Am Rev Respir Dis 1993;147:962-6. (2+).
181. Alfageme I, Vazquez R. Ventricular fibrillation after intrapleural urokinase. Intensive Care Med 1997;23:352. (3).
182. Frye MD, Jarratt M, Sahn SA. Acute hypoxemic respiratory failure following intrapleural thrombolytic therapy for hemothorax. Chest 1994;105:1595-6. (3).
183. Light RW, Nguyen T, Mulligan ME, et al. The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung 2000;178:13-18. (2+).
184. Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest 2000;117:1728-33. (2+).
185. Frederiksen B, Pressler T, Hansen A, et al. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006;95:1070-4. (1+).
186. Parks QM, Young RL, Poch KR, et al. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol 2009;58:492-502. (2+).
187. Whitchurch CB, Tolker-Nielsen T, Ragas PC, et al. Extracellular DNA required for bacterial biofilm formation. Science 2002;295:1487. (2+).
188. Evans AL, Gleeson FV. Radiology in pleural disease: state of the art. Respirology 2004;9:300-12. (4).
189. Millar AB, Boothroyd AE, Edwards D, et al. The role of computed tomography (CT) in the investigation of unexplained haemoptysis. Respir Med 1992;86:39-44. (3).
190. Naidich DP, Lee JJ, Garay SM, et al. Comparison of CT and fiberoptic bronchoscopy in the evaluation of bronchial disease. AJR Am J Roentgenol 1987;148:1-7. (3).
191. Naidich DP, Harkin TJ. Airways and lung: correlation of CT with fiberoptic bronchoscopy. Radiology 1995;197:1-12. (4).
192. Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med 2006;27:193-213. (4).
193. Woodring JH. Determining the cause of pulmonary atelectasis: a comparison of plain radiography and CT. AJR Am J Roentgenol 1988;150:757-63. (3).
194. McLoud TC. CT and MR in pleural disease. Clin Chest Med 1998;19:261-76. (4).
195. Moulton AL. Surgical definition of pleural peel. Radiology 1991;178:889-90. (4).
196. Neff CC, vanSonnenberg E, Lawson DW, et al. CT follow-up of empyemas: pleural peels resolve after percutaneous catheter drainage. Radiology 1990;176:195-7. (3).
197. Kearney SE, Davies CW, Tattersall DJ, et al. The characteristics and significance of thoracic lymphadenopathy in parapneumonic effusion and empyema. Br J Radiol 2000;73:583-7. (3).
198. Pothula V, Krellenstein DJ. Early aggressive surgical management of parapneumonic empyemas. Chest 1994;105:832-6. (3).
199. Bilgin M, Akcali Y, Oguzkaya F. Benefits of early aggressive management of empyema thoracis. Aust NZ J Surg 2006;76:120-2. (1-).
200. Jimenez CD, Diaz G, Perez-Rodriguez E, et al. Prognostic features of residual pleural thickening in parapneumonic pleural effusions. Eur Respir J 2003;21:952-5. (2+).
201. Martinez MA, Cordero PJ, Cases E, et al. Prognostic features of residual pleural thickening in metapneumonic pleural effusion. Arch Bronconeumol 1999;35:108-12. (2).
202. Amin R. Non-Hodgkin's lymphoma complicating chronic pyothorax. J R Soc Med 1999;92:89-90. (3).
203. Aozasa K, Takakuwa T, Nakatsuka S. Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation. Adv Anat Pathol 2005;12:324-31. (4).
204. Aozasa K. Pyothorax-associated lymphoma. J Clin Exp Hematol 2006;46:5-10. (3).
205. Iuchi K, Aozasa K, Yamamoto S, et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol 1989;19:249-57. (3).
206. Iuchi K, Ohsawa M, Tomita Y, et al. Angiomatous lesions in the wall of chronic pyothorax. Mod Pathol 1995;8:417-20. (3).
207. Kanno H, Aozasa K. Mechanism for the development of pyothorax-associated lymphoma. Pathol Int 1998;48:653-64. (4).
208. Nakatsuka S, Nishiu M, Tomita Y, et al. Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL) Jpn J Cancer Res 2002;93:411-16. (3).
209. Narimatsu H, Ota Y, Kami M, et al. Clinicopathological features of pyothoraxassociated lymphoma; a retrospective survey involving 98 patients. Ann Oncol 2007;18:122-8. (3).
210. O'Donovan M, Silva I, Uhlmann V, et al. Expression profile of human herpesvirus 8 (HHV-8) in pyothorax associated lymphoma and in effusion lymphoma. Mol Pathol 2001;54:80-5. (3).
211. Sasajima Y, Yamabe H, Kobashi Y, et al. High expression of the Epstein-Barr virus latent protein EB nuclear antigen-2 on pyothorax-associated lymphomas. Am J Pathol 1993;143:1280-5. (2-).
212. Johnson PH, Macfarlane JT. Commentary: pleural empyema and malignancyeanother dimension. Thorax 1996;51:107-8. (4).